Kadmon (KDMN) Stock Price Down 21.3%
Kadmon Holdings Inc (NYSE:KDMN) traded down 21.3% during mid-day trading on Tuesday . The stock traded as low as $3.75 and last traded at $3.81. 6,473,028 shares changed hands during trading, an increase of 365% from the average session volume of 1,391,423 shares. The stock had previously closed at $4.84.
KDMN has been the topic of a number of research reports. Piper Jaffray Companies reissued a “positive” rating and set a $9.00 target price (up from $7.00) on shares of Kadmon in a report on Tuesday. Zacks Investment Research lowered shares of Kadmon from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Jefferies Group boosted their target price on shares of Kadmon to $16.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Kadmon in a report on Friday, December 15th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $10.21.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN grew its holdings in Kadmon by 17.0% during the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after acquiring an additional 8,742 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Kadmon by 66.6% during the 4th quarter. Bank of New York Mellon Corp now owns 59,430 shares of the company’s stock worth $216,000 after acquiring an additional 23,763 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in Kadmon during the 2nd quarter worth approximately $114,000. Old West Investment Management LLC bought a new stake in Kadmon during the 3rd quarter worth approximately $169,000. Finally, BlueCrest Capital Management Ltd bought a new stake in Kadmon during the 4th quarter worth approximately $241,000. 51.91% of the stock is currently owned by hedge funds and other institutional investors.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.